Significance of tumour regression in lymph node metastases of gastric and gastro-oesophageal junction adenocarcinomas.


Journal

The journal of pathology. Clinical research
ISSN: 2056-4538
Titre abrégé: J Pathol Clin Res
Pays: England
ID NLM: 101658534

Informations de publication

Date de publication:
10 2020
Historique:
received: 03 04 2020
revised: 10 04 2020
accepted: 14 04 2020
pubmed: 14 5 2020
medline: 14 10 2021
entrez: 14 5 2020
Statut: ppublish

Résumé

The presence of lymph node (LN) metastases is one of the most important negative prognostic factors in upper gastrointestinal carcinomas. Tumour regression similar to that in primary tumours can be observed in LN metastases after neoadjuvant therapy. We evaluated the prognostic impact of histological regression in LNs in 480 adenocarcinomas of the stomach and gastro-oesophageal junction after neoadjuvant chemotherapy. Regressive changes in LNs (nodular and/or hyaline fibrosis, sheets of foamy histiocytes or acellular mucin) were assessed by histology. In total, regressive changes were observed in 128 of 480 patients. LNs were categorised according to the absence or presence of both residual tumour and regressive changes (LN-/+ and Reg-/+). 139 cases were LN-/Reg-, 28 cases without viable LN metastases revealed regressive changes (LN-/Reg+), 100 of 313 cases with LN metastases showed regressive changes (LN+/Reg+), and 213 of 313 metastatic LN had no signs of regression (LN+/Reg-). Overall, LN/Reg categorisation correlated with overall survival with the best prognosis for LN-/Reg- and the worst prognosis for LN+/Reg- (p < 0.001). LN-/Reg+ cases had a nearly significant better outcome than LN+/Reg+ (p = 0.054) and the latter had a significantly better prognosis than LN+/Reg- (p = 0.01). The LN/Reg categorisation was also an independent prognostic factor in multivariate analysis (HR = 1.23; 95% CI 1.1-1.38; p < 0.001). We conclude that the presence of regressive changes after neoadjuvant treatment in LNs and LN metastases of gastric and gastro-oesophageal junction cancers is a relevant prognostic factor.

Identifiants

pubmed: 32401432
doi: 10.1002/cjp2.169
pmc: PMC7578278
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

263-272

Informations de copyright

© 2020 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.

Références

Cancer. 2003 Oct 1;98(7):1521-30
pubmed: 14508841
Virchows Arch. 2016 Apr;468(4):425-30
pubmed: 26754675
Ann Surg. 2011 May;253(5):934-9
pubmed: 21490451
Ann Surg. 2012 Dec;256(6):1002-7
pubmed: 22968067
Ann Surg. 2013 Nov;258(5):784-92; discussion 792
pubmed: 24045450
Ann Surg Oncol. 2012 Jul;19(7):2108-18
pubmed: 22130620
Ann Surg Oncol. 2003 Aug;10(7):734-9
pubmed: 12900363
Br J Cancer. 2016 Sep 6;115(6):655-63
pubmed: 27537382
Eur J Surg Oncol. 2017 Sep;43(9):1607-1616
pubmed: 28347525
Ann Thorac Surg. 2011 Dec;92(6):2020-7
pubmed: 22115212
J Am Coll Surg. 2012 Jan;214(1):88-96
pubmed: 22036661
Mod Pathol. 2018 Jan;31(1):4-23
pubmed: 28776577
World J Gastroenterol. 2015 Dec 28;21(48):13500-6
pubmed: 26730161
Virchows Arch. 2018 Feb;472(2):175-186
pubmed: 28918544
Br J Surg. 2018 Nov;105(12):1639-1649
pubmed: 30047556
Eur J Surg Oncol. 2007 Aug;33(6):724-8
pubmed: 17336482
J Clin Oncol. 2016 Aug 10;34(23):2721-7
pubmed: 27298411
J Clin Oncol. 2013 Jan 10;31(2):263-71
pubmed: 23213098
Hum Pathol. 2019 Feb;84:26-34
pubmed: 30217622
Ann Surg. 2007 Apr;245(4):543-52
pubmed: 17414602
Ann Thorac Surg. 2015 Jan;99(1):277-83
pubmed: 25442991
Br J Surg. 1998 Nov;85(11):1457-9
pubmed: 9823902
Lancet Oncol. 2016 Dec;17(12):1697-1708
pubmed: 27776843
J Clin Oncol. 2011 Jun 10;29(17):2364-71
pubmed: 21537040
Semin Thorac Cardiovasc Surg. 2016 Summer;28(2):549-558
pubmed: 28043475
Histopathology. 2018 Jun;72(7):1180-1188
pubmed: 29465751
World J Gastrointest Oncol. 2019 Jan 15;11(1):48-58
pubmed: 30984350
Mod Pathol. 2020 Apr;33(4):676-689
pubmed: 31673084

Auteurs

Daniel Reim (D)

Department of Surgery, Klinikum Rechts der Isar, TUM School of Medicine, Munich, Germany.

Alexander Novotny (A)

Department of Surgery, Klinikum Rechts der Isar, TUM School of Medicine, Munich, Germany.

Helmut Friess (H)

Department of Surgery, Klinikum Rechts der Isar, TUM School of Medicine, Munich, Germany.

Julia Slotta-Huspenina (J)

Institute of Pathology, Technische Universität München, Munich, Germany.

Wilko Weichert (W)

Institute of Pathology, Technische Universität München, Munich, Germany.

Katja Ott (K)

RoMed Klinikum Rosenheim, Rosenheim, Germany.

Bastian Dislich (B)

Institute of Pathology, University of Bern, Bern, Switzerland.

Sylvie Lorenzen (S)

3rd Department of Internal Medicine, Hematology/Medical Oncology, Klinikum rechts der Isar, TUM School of Medicine, Munich, Germany.

Karen Becker (K)

Institute of Pathology, Technische Universität München, Munich, Germany.

Rupert Langer (R)

Institute of Pathology, University of Bern, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH